Key Drivers
- High current ratio
- Severe cash depletion
- Persistent net losses
AIAI Summary
MNMD has become an event‑driven late‑stage biotech where 2026 Phase III readouts and subsequent financing cadence now concentrate virtually all upside—position only as a high‑conviction, size‑limited trade and pre‑plan for likely dilution or hedges if trials slip or disappoint. Monitor cash runway against trial milestones and treat any missed timeline or mixed readout as a trigger to reassess or reduce exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High current ratio
- •Severe cash depletion
- •Persistent net losses
MNMD has strong short-term liquidity and low leverage on paper but faces zero revenue, sustained heavy losses and a dramatic cash drawdown to ~$20M by 2025-09-30, creating a material funding risk.
Price Behavior
Key Price Behavior Insights:
- •Above SMA
- •Constructive RSI
- •Tight resistance
Price is above its short-term average with constructive RSI, facing near-term resistance at $18.60–$19.05 and support at $16.90–$17.20, where a decisive break below would flip the short-term bias bearish.
Recent high at $19.05 on 2026-03-10 sits very close to current price, compressing upside
Sentiment & News
Similar Companies in Healthcare
Other companies in the same sector with AI ratings